Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Lactotripeptide, specifically the tripeptides Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) derived from milk proteins, have been studied for their effects on cardiovascular health, including arteriosclerosis. These peptides act as natural angiotensin-converting enzyme (ACE) inhibitors, which can help lower blood pressure—a major risk factor for arteriosclerosis. Several randomized controlled trials and meta-analyses have demonstrated that supplementation with lactotripeptides can lead to modest but statistically significant reductions in systolic and diastolic blood pressure in both hypertensive and normotensive individuals. Lowering blood pressure may contribute to reduced arterial stiffness and slowed progression of arteriosclerosis. However, direct evidence linking lactotripeptide supplementation to the prevention or treatment of arteriosclerosis (the thickening and hardening of arterial walls) is limited. Most studies focus on surrogate markers such as blood pressure and arterial stiffness (e.g., pulse wave velocity, augmentation index), rather than direct measures of atherosclerotic plaque or clinical cardiovascular outcomes. Overall, lactotripeptides are supported by a moderate level of scientific evidence for improving vascular function and lowering blood pressure, which are relevant to arteriosclerosis risk, but the evidence for direct effects on arteriosclerosis itself remains incomplete.

More about Lactotripeptide
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by Lactotripeptide

Products containing Lactotripeptide